SCHEMBL1551929

SCHEMBL1551929

CC(C)(C)OC(=O)N1CCO[C@H](Cc2cc(Br)cc(Br)c2O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHA2 P29317 4/20 0.46
ERBB2 P04626 1/20 0.39
EPHB4 P54760 1/20 0.39
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
USP30 Q70CQ3 2/20 0.37
GFER P55789 1/20 0.36
P2RX3 P56373 3/20 0.36
P2RX2 Q9UBL9 3/20 0.36
PDE4B Q07343 1/20 0.36
DPP4 P27487 1/20 0.35
RECQL P46063 1/20 0.35
LMNA P02545 1/20 0.35
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27695130 0.85 EPHA2 (0.47) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL1551911 0.85 EPHA2 (0.47) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL1552706 0.82 EPHA2 (0.49) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL1551905 0.81 EPHA2 (0.46) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL31076496 0.79 EPHA2 (0.51) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL25703542 0.79 EPHA2 (0.51) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL1553137 0.79 EPHA2 (0.44) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL1553166 0.79 EPHA2 (0.44) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL1552545 0.78 KDM1A (0.41) EPHA2ERBB2EPHB4USP2SMN1; SMN2
SCHEMBL27695185 0.78 KDM1A (0.41) EPHA2ERBB2EPHB4USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844026-B1 MORPHOLINES AS 5HT2C AGONISTS HOFFMANN LA ROCHE (CH) 2011-04-27 EP disclosed
US-7323466-B2 Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HOFFMAN-LA ROCHE INC. (US) 2008-01-29 US disclosed
US-7323466-B2 Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HOFFMAN-LA ROCHE INC. (US) 2008-01-29 US disclosed
US-7323466-B2 Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HOFFMAN-LA ROCHE INC. (US) 2008-01-29 US disclosed
EP-1844026-A2 MORPHOLINES AS 5HT2C AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-17 EP disclosed
US-20060178510-A1 New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HOFFMANN-LA ROCHE INC. 2006-08-10 US disclosed
WO-2006077025-A2 MORPHOLINES AS 5HT2C AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178510-A1 New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity HTR2C, HTR1A, HTR1B EPHA2 3530/4885ERBB2 1770/4885EPHB4 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.